<DOC>
	<DOCNO>NCT01733121</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability NBI-98854 ( titrate subject 's optimal dose range 25 75 mg ) administer daily treatment Tardive Dyskinesia ( TD ) symptom .</brief_summary>
	<brief_title>NBI-98854 Dose Titration Study Treatment Tardive Dyskinesia</brief_title>
	<detailed_description>This Phase 2 , randomize , double-blind , placebo-controlled , dose-titration study evaluate efficacy , safety , tolerability NBI-98854 ( titrate subject 's optimal dose range 25 75 mg ) compare placebo , administer daily ( q.d . ) total 6 week treatment . Approximately 90 medically stable male female subject one follow clinical diagnosis enrol : schizophrenia schizoaffective disorder neuroleptic-induced TD ; mood disorder neuroleptic-induced TD ; gastrointestinal disorder metoclopramide-induced TD . For subject randomize active treatment , start dose 25 mg NBI 98854 , may escalate increment 25 mg every 2 week maximum 75 mg achieve optimal dose NBI-98854 subject</detailed_description>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<criteria>Have one follow clinical diagnosis least 3 month prior screen ) schizophrenia schizoaffective disorder ; b ) mood disorder ; c ) gastrointestinal disorder ( e.g. , gastroparesis , gastroesophageal reflux disease ) Have clinical diagnosis neurolepticinduced tardive dyskinesia least 3 month prior screen . Be receive stable dose antipsychotic medication minimum 30 day study start . Subjects use antipsychotic medication must stable psychiatric status . Have dos concurrent medication condition treat stable minimum 30 day study start expect remain stable study . Subjects childbearing potential must agree use hormonal two form nonhormonal birth control study . Female subject must pregnant . Be good general health expect complete clinical study design . Have body mass index ( BMI ) 18 38 kg/m2 ( inclusive ) . Have negative urine drug screen ( negative amphetamine , barbiturate , benzodiazepine , phencyclidine , cocaine , opiates , cannabinoids ) screen study start , except subject receive stable dose benzodiazepine . Have negative alcohol breath test screening study start . Have active clinically significant unstable medical condition within 1 month ( 30 day ) prior screen . Have history substance dependence substance ( drug ) alcohol abuse within 3 month study start ( nicotine caffeine dependence exclusionary ) . Have know history neuroleptic malignant syndrome . Have significant risk suicidal violent behavior . Receiving exclude concomitant medication reserpine , metoclopramide , stimulant , tetrabenazine . Receiving medication treatment tardive dyskinesia . Have positive human immunodeficiency virus antibody , ( HIVAb ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody result screen history positive result . Have receive investigational drug within 30 day screen plan use investigational drug ( NBI98854 ) study . Have allergy , hypersensitivity , intolerance tetrabenazine . Have previous exposure NBI98854 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>